PT-141 is strictly for laboratory research and is commonly employed in the following investigational areas:

Male Erectile Dysfunction Models

Research models utilize PT-141 to evaluate its efficacy in restoring or enhancing erectile function. Investigations focus on both intranasal and subcutaneous administration routes in subjects with mild-to-moderate erectile dysfunction, particularly evaluating its pharmacodynamic effects in populations exhibiting an inadequate response to PDE5 inhibitors like sildenafil.

Hypoactive Sexual Desire Disorder (HSDD)

Experimental protocols employ this peptide to characterize its neurobiological mechanisms in female sexual dysfunction. Studies assess its role in the treatment of HSDD in premenopausal models, measuring central nervous system responses and behavioral indicators of increased sexual desire and arousal.

Behavioral Neurobiology and Sexual Solicitation

In animal behavioral studies, PT-141 is used to investigate specific mating behaviors. Researchers evaluate the central pathways involved when the melanocortin receptor agonist selectively facilitates proceptive behaviors and sexual solicitation, such as in female rat models.

Pathway / Mechanistic Context

The primary mechanism of action for PT-141 in research settings involves its direct binding and activation of central melanocortin receptors to modulate neurogenic sexual responses.

• Central Receptor Activation: Penetrates the central nervous system to act as a direct agonist at MC3 and MC4 receptors located in the hypothalamus and other relevant brain regions.
• Neural Pathway Stimulation: Receptor activation stimulates downstream neural signaling, including dopaminergic pathways in the medial preoptic area.
• Arousal and Desire Induction: Triggers central neurogenic pathways that facilitate sexual arousal, proceptive behaviors, and the physiological responses necessary for erectile function without relying on direct vascular dilation.

Preclinical Research Summary

Published preclinical and clinical-translational literature documents the investigation of PT-141 across diverse behavioral and physiological models of sexual dysfunction.

• Double-blind, placebo-controlled trials demonstrated that intranasal and subcutaneous PT-141 safely and effectively induced pharmacological responses in healthy males and patients with mild-to-moderate erectile dysfunction, including those unresponsive to Viagra®.
• In animal models, administration of the melanocortin receptor agonist resulted in the selective facilitation of sexual solicitation behaviors in female rats.
• Comprehensive reviews of melanocortins highlight PT-141’s viability as a novel, centrally-acting agent for the treatment of both male and female sexual dysfunction.
• Neurobiological studies confirm the specific role of bremelanotide in targeting central pathways to treat hypoactive sexual desire disorder in premenopausal cohorts.

Form & Analytical Testing

• Solid-Phase Peptide Synthesis
• Lyophilization
• Identity Verification: Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the purity standard.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Diamond, L., Earle, D., Rosen, R., Willett, M., & Molinoff, P. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16, 51-59. https://doi.org/10.1038/sj.ijir.3901139.
• Rosen, R., Diamond, L., Earle, D., Shadiack, A., & Molinoff, P. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. International Journal of Impotence Research, 16, 135-142. https://doi.org/10.1038/sj.ijir.3901200.
• Pfaus, J., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.. Proceedings of the National Academy of Sciences of the United States of America, 101 27, 10201-4 . https://doi.org/10.1073/PNAS.0400491101.
• Shadiack, A., Sharma, S., Earle, D., Spana, C., & Hallam, T. (2007). Melanocortins in the treatment of male and female sexual dysfunction.. Current topics in medicinal chemistry, 7 11, 1137-44 . https://doi.org/10.2174/156802607780906681.
• Pfaus, J. G., Sadiq, A., Spana, C., & Clayton, A. H. (2022). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 27(3), 281–289. https://doi.org/10.1017/S109285292100002X.

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.